In short. An audience with no findings is an audience with no baseline. What the shift in age changes about the advice, and what it does not.
Key points
- There is a practical point underneath this.
- A standardised record taken before anything is done is what makes every later comparison possible.
- Treating early uses up that baseline — and it does so for a benefit that cannot be measured, which is the opposite of what the evidence would support.
Prejuvenation is aimed at younger patients, and there are two reasons for that. One is sound and the other is commercial, and they arrive in the same message.
The sound reason
Prevention does more good when it starts early, and for the measures that actually work that is unambiguously true. Sun exposure accumulates over decades, much of the damage visible at forty is the record of exposure in the twenties, and protection begun young prevents more than protection begun later. Not smoking works the same way. So the instinct that early action is better is correct, and it is correct for the two interventions that need nothing clinical.
The commercial reason
An audience with no findings is an audience with no baseline. Nothing can be photographed, nothing can be measured, and nothing can be shown not to work. For a treatment whose benefit cannot be demonstrated, that is the ideal population, because the absence of evidence is invisible: there is no finding to improve, so the absence of an improvement is not noticeable either.
A face that has never been treated is the best baseline available
There is a practical point underneath this. A standardised record taken before anything is done is what makes every later comparison possible. Treating early uses up that baseline — and it does so for a benefit that cannot be measured, which is the opposite of what the evidence would support.
What the shift in age changes
It changes what the honest advice is. For a younger person with healthy skin and no specific concern, the advice with evidence behind it is sun protection, not smoking, and a baseline photograph. It is unglamorous, it costs little, and it is supported by studies that run for years in whole populations. For a younger person with a specific finding, the finding can be assessed on its own terms, which is a different and better-defined proposition than a prevention programme.
What it does not change
The labelled risks. Every intervention in this category carries them whether or not the person has a finding, and a young person accepting them for an unmeasurable benefit is accepting a worse trade than an older person accepting them for a visible one. That is the sentence the marketing does not contain, and it is the one worth carrying into a consultation.
What a younger patient is being asked to weigh
- Real, labelled risks of an intervention, accepted now.
- A benefit that cannot be measured, now or later.
- The loss of an untreated baseline that would have made every later comparison possible.
None of that makes treatment wrong. It makes the trade explicit, which is what the category tends not to do.
Frequently asked questions
Why is prejuvenation aimed at younger patients?
Partly because prevention sounds most reasonable when started early, and partly because an audience with no findings is an audience with no baseline, so nothing can be shown not to work. The first is a sound instinct and the second is a commercial advantage, and they are transmitted in the same message.
Does starting earlier give a bigger benefit?
For sun protection and not smoking, yes, and by a wide margin, because exposure accumulates over decades and avoiding it early prevents the most. For everything else in the category the claim has not been tested: it assumes the mechanism interacts with age in a way nobody has measured.
Is there anything to lose by treating young skin?
The labelled risks of whatever is used, accepted for a benefit that cannot be measured, and the possibility that a face with no findings is being treated for a category rather than for a problem. There is also the practical point that a baseline record is lost: a face that has never been treated is the clearest baseline a person will ever have.
Risks & Limitations
- A face with no findings has no measurable baseline, so a preventive benefit cannot be demonstrated while the risks of treatment remain real.
- Nothing is approved with a preventive indication for facial ageing; approvals are for treating a change that is already present.
- Sun protection and not smoking are the only preventive measures with substantial support, and neither needs a clinical treatment.
- Treating early or maintaining a result is not prevention, and repeated treatment accumulates the labelled risks.
- A claim that nothing could contradict is a claim that cannot be supported either, and this category's claims are of that kind.
When to Seek Care
- A mole or patch that is changing in size, shape or colour — have it assessed by a clinician.
- A lesion that bleeds, itches or will not heal — have it assessed by a clinician.
- Blistering, crusting or pigment change that follows a device treatment — have it assessed by a clinician.
- Severe pain, dusky or mottled skin, or a change in vision after an injection — seek emergency care immediately.
References & Further Reading
- World Health Organization (WHO) — ultraviolet radiation and skin cancer prevention guidance
- U.S. Food and Drug Administration (FDA) — approved products and devices and their labelled indications
- National Medical Products Administration (NMPA, China) — approved products and their indications
- Cochrane Library — systematic reviews of photoprotection and topical treatments
- Chinese Medical Association Dermatology Branch — clinical guidance
This page is a review of published evidence and regulation, not medical advice, and it does not cite individual studies. It is not a booking page and it does not recommend a treatment, for or against. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.